2022 Community Oncology Conference
S

Treatment Conundrums in Myeloma

By 2022 Community Oncology Conference FEATURING Sergio Giralt
June 7, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Total Health

Best of Hematology

Sat, Mar 25, 2023
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
05:56
ASH 2022 Conference Coverage

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

Feat. G. Morgan
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
04:31
ASH 2022 Conference Coverage

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …

Feat. A. Chari
15:54
Paul Richardson

Emerging Strategies in the Management of Relapsed MM

30:59
Houston Methodist Hospital

Overview of Advances in Multiple Myeloma

Feat. S. Ganguly
09:09
Douglas W. Sborov

IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…

21:38
Rahul Banerjee

CAR-T Therapy in Myeloma: What's Here and What's Coming So…

34:48
Kenneth Anderson

MM Cured in 2030 - What Are the Next Steps?

Feat. K. Anderson
06:58
Saurabh Chhabra

Summary of the MAMMOTH Trial in R/R Myeloma

06:41
Hamza Hashmi

Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…

10:08
ASH 2022 Conference Coverage

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…

Feat. N. Korde
21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
24:19
Dana-Farber Cancer Institute

Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…

Feat. P. Richardson
45:43
MedNews Week

Multiple Myeloma in 2022: Developments, Directions, and Disparities

Feat. J. Mikhael
24:01
ASH 2022 Conference Coverage

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…

Feat. Y. Efebera
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
14:41
Zhubin Gahvari

MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs

06:16
ASH 2022 Conference Coverage

ASH 2022 U.S. Myeloma CAR-T Consortium Real World Experience: Factor…

Feat. H. Hashmi